Energetic and functional contribution of residues in the core binding factor beta (CBFbeta ) subunit to heterodimerization with CBFalpha.
about
The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.A structure-based benchmark for protein-protein binding affinityCooperative binding of DNA and CBFbeta to the Runt domain of the CBFalpha studied via MD simulations.Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradationMutagenesis of the Runt domain defines two energetic hot spots for heterodimerization with the core binding factor beta subunitThe Runx3 distal transcript encodes an additional transcriptional activation domainStructure and Biophysics of CBFβ/RUNX and Its Translocation Products.Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven CancersDisease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles.A mutation in the S-switch region of the Runt domain alters the dynamics of an allosteric network responsible for CBFbeta regulation.Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interactionRUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).Runx transcription factors repress human and murine c-Myc expression in a DNA-binding and C-terminally dependent manner.Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11.Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice.RUNX2 mutations in Chinese patients with cleidocranial dysplasia.Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.The molecular signature of oncofusion proteins in acute myeloid leukemia.Regulation of RUNX2 transcription factor-DNA interactions and cell proliferation by vitamin D3 (cholecalciferol) prohormone activity.Optimization of proximity ligation assay (PLA) for detection of protein interactions and fusion proteins in non-adherent cells: application to pre-B lymphocytes.RUN-CBFbeta interaction in C. elegans: computational prediction and experimental verification.CHD7 deficiency delays leukemogenesis in mice induced by CBFB-MYH11.CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression.Energetic contribution of residues in the Runx1 Runt domain to DNA binding.Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia.
P2860
Q24554277-CA5C4E31-EFA8-48F6-9D57-0A8DC0894BC8Q24631621-62B58B09-02D2-4AF7-8F94-A7396014C18EQ24814788-70AA8195-C5AA-4285-A4D4-437497A9369BQ28348865-5385A101-740A-4B9D-B0A9-6F57D5C5491AQ28590672-019239A0-2439-43E9-9AC4-201112EED2DEQ28590965-0E1CCC30-230F-4B34-B871-44F72A41E7D4Q30252939-D82353AE-D0C9-47AC-A87E-454EAE79F6A4Q30276341-84F74AA9-7DFC-4503-9463-4D9DC3FAC8B3Q30443541-67EAB8C5-DA29-408F-8451-C3933F0333E3Q30444099-C3B08529-707C-4232-A3FC-06F725CC03BCQ33680301-BA943910-B25D-45F5-912F-D1E7A06CCC49Q33794291-F3473CB9-C9E1-4611-A3CC-FF864DFEBA08Q34388355-C552596D-9119-450E-AF33-0D3EF6E86E78Q34621037-BE1CFFEF-5336-4540-A6BA-66E69DBF801FQ34852828-BA29387A-3E11-4ED4-BDD3-83A31B5FFADAQ35687836-52CAE4F2-7189-41C0-98B8-85B3D1CA3A9CQ35779737-39EAA3D9-6C83-4D93-9A5F-921ADA2E4B44Q35920680-B504DCC2-12EF-4BFE-A1B6-FABE69768E11Q37325296-CC3CFA0F-34BD-4A6C-9C18-10EBE0AE35F3Q37662400-D6452A5F-176A-49A4-9E12-979E3A77D0CBQ37730254-74084DC6-E672-4136-973D-AF2AE092D0C2Q38329289-A94D0A6D-755B-45DA-BF18-F5EA899E2AAFQ41079720-BA89D8F2-77BD-4972-B39E-729AC565D388Q42608208-3C5CC9C4-C60E-4844-8CFF-7DF4BDB895E3Q42778080-EC542612-5B5D-4D64-AACD-C0AF29E97857Q43239447-D5603C54-7987-4741-A1B3-8D6611A35DC1Q44478788-3647EE36-55E2-4108-B4CC-72685CB8A79AQ47127883-645B49E2-FB99-410A-B260-6BE4E7F0F28AQ52725909-ECEA58BE-2E12-4F68-8B9E-6CC892DBF809Q53821842-391CF4BD-FA53-4395-8C3E-27684F1F9CAB
P2860
Energetic and functional contribution of residues in the core binding factor beta (CBFbeta ) subunit to heterodimerization with CBFalpha.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Energetic and functional contr ...... erodimerization with CBFalpha.
@en
Energetic and functional contribution of residues in the core binding factor beta
@nl
type
label
Energetic and functional contr ...... erodimerization with CBFalpha.
@en
Energetic and functional contribution of residues in the core binding factor beta
@nl
prefLabel
Energetic and functional contr ...... erodimerization with CBFalpha.
@en
Energetic and functional contribution of residues in the core binding factor beta
@nl
P2093
P2860
P356
P1476
Energetic and functional contr ...... erodimerization with CBFalpha.
@en
P2093
Bushweller JH
P2860
P304
39579-39588
P356
10.1074/JBC.M007350200
P407
P577
2000-12-01T00:00:00Z